AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06712186 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (Placebo)
Description: The Placebo group / group C will be administer Normal Saline without any active medication over 10 min to patients, 2 minutes prior to Endotracheal intubation using laryngoscopy to compare its effect to those of Dexmedetomidine in attenuating the pressor response to laryngoscopy.
Study NCT06718387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PsychoEducation Program
Description: 6 sessions of PsychoEducational Program
Study NCT06731712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Function Exercises
Description: Physical function interventions included strength, balance, and mobility exercises. More specifically, the exercises include progressively increasing intensity strengthening exercises with a resistance band for the following muscle groups: hip abductor and extensor muscles, knee flexor and extensor muscles, and shoulder abductor and external rotator muscles. Other exercises consist of standing calf raises, squats, bridges, and push-ups. Additionally, functional exercises include heel-to-toe standing or walking, single-leg standing, stepping over obstacles, bending down, and lifting an object with feet together.
Study NCT06731595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: colchicine 0.6mg oral twice daily for 7 days
Study NCT04158973 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine VTE prophylaxis in hospital
Description: Patients randomized to the standard treatment (Control) group will receive routine VTE prophylaxis according to current guidelines and clinical practices, VTE risk assessment and prophylaxis if indicated during hospitalization according to current policies for hospitals in China but no further treatment prophylaxis after discharge
Study NCT06309264 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phonak Lumina P90
Description: FDA approved hearing aid with gain settings determined either by speech-based audiometry or conventional fitting methods (NAL-NL2). Other features such as noise reduction and directional microphones are disabled for the duration of the study.
Study NCT06309264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak Lumina P90
Description: FDA approved hearing aid with gain settings determined either by speech-based audiometry or conventional fitting methods (NAL-NL2). Other features such as noise reduction and directional microphones are disabled for the duration of the study.
Study NCT06077877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4524101
Description: GSK452101 will be administered.
Study NCT06077877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered.
Study NCT06730308 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Hypofractionated radiotherapy
Study NCT06730308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy
Description: weekly albumin-bound paclitaxel (50 mg/m²) and cisplatin (25 mg/m²)
Study NCT06730308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone 2mg/kg, qd, concurrent with radiotherapy
Study NCT06730282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danggui Shaoyao San (DSS)
Description: Danggui Shaoyao San is a traditional Chinese medicine (TCM) formula used to regulate blood flow, alleviate pain, and reduce inflammation. Participants in this arm will receive DSS starting 3 to 7 days before menstruation and continue until 3 days after menstruation for two cycles.
Study NCT06730282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cuscuta Chinensis (Tu Si Zi)
Description: Cuscuta Chinensis is a TCM formula traditionally used to nourish kidney essence and improve menstrual health. Participants in this arm will receive Tu Si Zi starting 3 to 7 days before menstruation and continue until 3 days after menstruation for two cycles.
Study NCT06077877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niraparib
Description: Niraparib will be administered.
Study NCT06730282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Therapy (DSS + Tu Si Zi)
Description: This intervention combines Danggui Shaoyao San and Cuscuta Chinensis. Participants will receive both formulas starting 3 to 7 days before menstruation and continue until 3 days after menstruation for two cycles.
Study NCT06730282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in this arm will receive a placebo that matches the appearance of the study medications. The placebo will be administered on the same schedule as the active treatments for two menstrual cycles.
Study NCT06730165 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation
Description: Stimulation of the vagus nerve through the tragus and concha in the ear
Study NCT06730165 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation
Description: Stimulation of the vagus nerve through the tragus and concha in the ear
Study NCT06730165 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Auricular Trigeminal Nerve Stimulation
Description: Stimulation of the trigeminal nerve via the auriculotemporal nerve with a clip electrode from the upper auricle
Study NCT06038227 — intervention group
Intervention type: PROCEDURE
Intervention: Robotic Assisted Thoracic Surgery
Description: Surgeons will pre-determine to perform a segmentectomy or lobectomy using RATS.
Study NCT06038227 — intervention group
Intervention type: PROCEDURE
Intervention: Video Assisted Thoracic Surgery
Description: Surgeons will pre-determine to perform a segmentectomy or lobectomy using VATS.
Study NCT05989321 — intervention group
Intervention type: PROCEDURE
Intervention: PVI alone
Description: pulmonary vein isolation
Study NCT04915547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group-Based Exercise
Description: Each group session will consist of 10 to 18 participants and each exercise session will last 60 minutes and consist of four stages: (1) five minutes warm up (i.e. self-regulated walk); (2) twenty minutes of moderate intensity walking (3) thirty minutes of resistance training for the major muscles of the leg, trunk and arm and balance exercises that progress in difficulty; (4) five-minute cool down period (i.e. self-regulated walk). The exercise intensity will be assessed by one of the following criteria: 1) Resistance training - Point of volitional fatigue. Walking - Somewhat difficult (Borg at 3 to 4). The intensity will be increased according to the ACSM guideline.~The exercise was set up based on changes in instruments of evaluation of the older peoples as, Berg Balance Scale; Dynamic Gait Index and Timed Up and Go. In addition, exercises commonly used in primary health care groups. The protocol will take place in a gymnasium and will be supervised by a trained instructor.
Study NCT06730165 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Auricular Trigeminal Nerve Stimulation
Description: Stimulation of the trigeminal nerve via the auriculotemporal nerve with a clip electrode from the upper auricle
Study NCT06731491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concurrent Training
Description: Strength and aerobic training in the same training session for a period of 12 weeks, 3 times a week and with an average training time of 60 minutes
Study NCT06731491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage therapy and Aromatherapy
Description: Massage Therapy with Aromatherapy twice a week for a period of 12 weeks and an average time of 40 minutes per session.
Study NCT06505278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Receive Abiraterone plus prednisone/Enzalutamide/Apalutamide/Rezvilutamide in the evening
Description: Participants receive Abiraterone plus prednisone/Enzalutamide/Apalutamide/Rezvilutamide between 10:00 pm and 12:00 pm in the evening.
Study NCT04977414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Making Data Count Training intervention
Description: The Making Data Count training intervention was designed by NHS-Improvement to improve knowledge about SPC charts and to increase their uptake. Training sessions are tailored for two sets of attendees: board members and data analysts. Board member and analyst training sessions are delivered as close as possible in time, typically within the same month. Training sessions for board members are usually delivered over about one-and-a-half hours and focus more heavily on the benefits of control charts compared to other charts. Training sessions for analysts are usually delivered over three hours and focus more heavily on the structure and interpretation of the individual and moving range charts (X-mR charts).
Study NCT05247021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae block for group E
Description: . The patient will be placed in the prone position. A high-frequency linear probe or a curved array probe, depending on the BMI of the patient, will be placed in longitudinal alignment, 2-3cm lateral to the vertebral column. The transverse processes of the vertebrae at the level of surgery, the erector spinae muscle, and the psoas muscle will be identified. A 5- or 8-cm 22-G ultrasound needle will be inserted with an in-plane technique in a cephalad-to-caudal direction until bone contact with the top of the transverse process is reached. After slight retraction of the needle, 20ml of bupivacaine 0.25% will be injected behind the erector spinae muscle. The same procedure will be repeated on the contralateral side.
Study NCT05735912 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided radio frequency ablation
Description: Radiofrequency ablation performed under endoscopic ultrasound guidance of pancreatic insulinoma
Study NCT05735912 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgical resection of pancreatic insulinoma
Study NCT05940025 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MORT-LBP
Description: The MORT-LBP, developed by EverEx, Inc., is designed to provide multidisciplinary rehabilitation treatment, a combination of graded exercise therapy and cognitive behavioral therapy for patients with chronic lower back pain.
Study NCT05940025 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual (TAU)
Description: In the control group, education and physiotherapy is delivered and self-exercise is recommended.
Study NCT04916314 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Carbohydrate diet
Description: Second Nature is a three-month remote behavioural change programme with mentoring from a registered dietitian or nutritionist (health coach), encouraging adoption of a low energy, low-carbohydrate diet, peer group support, structured education articles and activity tracking technology. These elements are accessed via a smartphone or web-based application; each participant additionally receives an instructional handbook, and recipe book (+/-wireless weighing and activity tracking technology).
Study NCT04661514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Psilocybin-assisted psychotherapy
Study NCT05511558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Fosgonimeton
Description: Carbon-14 Radiolabeled Fosgonimeton
Study NCT05019885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Three times a week (M, W, F) for 2 consecutive weeks.
Study NCT05989321 — intervention group
Intervention type: PROCEDURE
Intervention: PVI + SPs ablation
Description: pulmonary vein isolation + SPs ablation
Study NCT06542159 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Online adaptive SBRT
Description: Online adaptive SBRT (without PTV expansion margin). The total dose will be 45-50Gy/3-4 fractions, administered once daily. FBCT and 4DCT will be acquired.
Study NCT06542159 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional SBRT
Description: SBRT with PTV expansion. The total dose will be 45-50Gy/3-4 fractions, administered once daily. CBCT will be acquired.
Study NCT05775913 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tubal Selective Delivery System (TSDS)
Description: A novel tubal selective delivery catheter system for selective delivery of administered agents to the fallopian tubes without entry of any portion of the catheter into the tubes.
Study NCT06161805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine hydrochloride
Description: Esketamine dosing regimen is set at 0.1 mg/kg/h as starting dosage. Dosage will be gradually increased based on heart rate, oxygen saturation, blood pressure and side effects (e.g. nausea and dissociative effects) during a period of 8 hours to a maximum of 0.5 mg/kg/h (in steps of 0.1-0.3-0.5 mg/kg/hour). This dosage regimen is similar to that used earlier by Sigtermans et al. \[1\].
Study NCT06161805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8 hour infusion with saline (NaCl 0.9%)
Study NCT04672356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI939
Description: IBI939 injection
Study NCT04672356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab injection
Study NCT05216224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-450
Description: Oral, small molecule MK2 inhibitor
Study NCT05216224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Placebo tablet manufactured to match ATI-450 in appearance
Study NCT05764239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB1934v1
Description: SYNB1934v1 consisted of powder for oral suspension packaged in sachets. During dose preparation, the powder was resuspended in water or apple juice prior to administration.
Study NCT05764239 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was manufactured using an inactive powder that was color matched to the SYNB1934v1 drug product. In order to maintain study blinding during the RWP, placebo was packaged, labeled, stored, and administered in an identical manner to SYNB1934v1.
Study NCT05088967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI110
Description: R2PD d1 IV every 3 weeks
Study NCT05088967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab
Description: 200mg d1 IV every 3 weeks
Study NCT05088967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sintilimab
Description: 200mg d1 IV every 3 weeks
Study NCT06479681 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer recovery coaching (PRC)
Description: The RC-Link peer recovery coaching intervention provides participants with an introduction to an RC-Link coach during their hospitalization. The RC-Link coach delivers coaching and support services for a 6-month period using a standardized PRC Checklist. During the baseline visit, the RC-Link coach first develops a personalized recovery plan with the participant that emphasizes multiple pathways to recovery, including different types of mutual aid groups, counseling, and alternative recovery tools. The approach empowers the participant with an actionable recovery plan that can be initiated upon discharge, but the plan can be modified as changes arise. After the initial baseline encounter, the RC-Link coach initiates phone, virtual, and/or in-person contact with the participant a minimum of twice weekly using the PRC Checklist to standardize service delivery.
Study NCT06479681 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Intervention (SBIRT)
Description: The control will receive a brief intervention, usual care (a referral list), contact information for the study team and hospital case management, and a follow-up contact at the end of the study period. The brief intervention entails (a) using motivational interviewing to gauge the individual's perspective of drinking, how it influences their life, and readiness for change; (b) provide information about the risks of hazardous drinking and potential ways to reduce drinking; (c) elicit their feedback; listen to their concerns; offer encouragement; encourage them to establish goals for behavior change; and (d) provide resources for change (e.g., the referral list). The referral list includes contact information for no-cost peer recovery coach through FAVOR that the participant could choose to call via self-referral. Thus, control participants are able to be linked to PRC, but they must initiate the call and initial visit outside the hospital setting.
Study NCT05593211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kronos Electrocautery Device
Description: The Kronos Electrocautery Device is a disposable electrocautery device that can cauterize deep tissue through a standard biopsy procedure guide needle. This device is intended to coagulate the tissue surrounding the core biopsy channel during withdrawal to reduce or eliminate significant post-procedural bleeding. Currently, the Kronos Electrocautery Device consists of one (1) size. As such, the existing Kronos Electrocautery Device is chosen as the worst-case condition
Study NCT05627752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide 40 MG
Description: Adding Enzalutamide to Docetaxel chemotherapy
Study NCT05627752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel injection
Description: Docetaxel chemotherapy
Study NCT05627752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel injection
Description: Docetaxel chemotherapy
Study NCT06239779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: The education intervention involves a brief PowerPoint presentation delivered by a physician, covering an overview of fibromyalgia, coping strategies, and the potential impact of smart phone addiction on fibromyalgia.
Study NCT06283667 — intervention group
Intervention type: DRUG
Intervention: Semaglutide
Description: Paricipants will be treated with commercially available Wegovy® according to routine clinical practice at the discretion of the treating physician, following approved label in Japan. The decision to initiate treatment with commercially available Wegovy® has been made by the patient and the treating physician before and independently from the decision to participate in this study.
Study NCT05554926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEF0117
Description: 2 mg AEF0117 containing approximately 100 μCi of \[4-14C\]AEF0117
Study NCT05687838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Music medicine
Study NCT05687838 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: Music medicine
Study NCT05479838 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention
Description: Coronary angiography will be performed via the femoral or radial artery, and primary PCI will be performed using standard guide catheters, guide wires, balloon catheters, and stents according to current guidelines. All PCI interventions performed by invasive cardiologists. The primary PCI type and contrast amount will be decided by the medical team. All patients will be treated by administering non-ionic, monomeric, low-osmolar iodinated iohexol as an intravascular contrast agent .
Study NCT04667715 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exablate BBBD
Description: Blood brain barrier disruption using ExAblate Type 2 device using microbubble resonators
Study NCT05056675 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENG block
Description: All patients will undergo the same preoperative, standardized protocol. Upon arrival to the operating room, patients will be placed in supine position. Routine, standard pre-medication will be applied before induction of general anesthesia. After intubation, the PENG block is performed. Under sonographic guidance using a curvilinear probe, puncture will be performed in a lateromedial direction until the needle tip reaches the plane between the iliopsoas tendon and periosteum and between the anterior inferior iliac spine and iliopubic eminence. After a negative aspiration test, the blinded test item will be injected in the plane beneath the iliopsoas muscle. Patients will be randomly assigned to receive the test item (20 mL of ropivacaine 0.5%, Naropin). The anesthesiologist and the surgeon are blinded to the product injected.
Study NCT05056675 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ll patients will undergo the same preoperative, standardized protocol. Upon arrival to the operating room, patients will be placed in supine position. Routine, standard pre-medication will be applied before induction of general anesthesia. After intubation, the PENG block is performed. Under sonographic guidance using a curvilinear probe, puncture will be performed in a lateromedial direction until the needle tip reaches the plane between the iliopsoas tendon and periosteum and between the anterior inferior iliac spine and iliopubic eminence. After a negative aspiration test, the blinded test item will be injected in the plane beneath the iliopsoas muscle. Patients will be randomly assigned to receive the placebo (20 mL of NaCL 0.9%). The anesthesiologist and the surgeon are blinded to the product injected.
Study NCT06223841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IAP0971
Description: IAP0971 should be subcutaneous injected，q3w